Abstract
The potential for life-threatening pneumonia due to respiratory syncytial virus (RSV) infection is recognised among patients with acute leukaemia and recipients of allogeneic or autologous bone marrow transplantation. RSV pneumonia has a high mortality rate in these settings. Less intensively treated patients are not usually considered to be at risk for serious RSV pneumonia. We describe the case of a 62-yr-old patient with chronic lymphocytic leukaemia (CLL) treated with fludarabine and cyclophosphamide who developed severe RSV pneumonia and recovered following treatment including intravenous ribavirin.
MeSH terms
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Agents / therapeutic use
-
Antiviral Agents / therapeutic use
-
Cyclophosphamide / adverse effects*
-
Cyclophosphamide / therapeutic use
-
Humans
-
Immunosuppressive Agents / adverse effects*
-
Immunosuppressive Agents / therapeutic use
-
Leukemia, Lymphocytic, Chronic, B-Cell / complications
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
-
Male
-
Middle Aged
-
Respiratory Syncytial Virus Infections / drug therapy
-
Respiratory Syncytial Virus Infections / etiology*
-
Ribavirin / therapeutic use
-
Vidarabine / adverse effects*
-
Vidarabine / analogs & derivatives*
-
Vidarabine / therapeutic use
Substances
-
Antineoplastic Agents
-
Antiviral Agents
-
Immunosuppressive Agents
-
Ribavirin
-
Cyclophosphamide
-
Vidarabine
-
fludarabine